Page 52 - ப்ரேசெனிுச் மருத்துவ பராமரிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vifor Pharma and Cara Therapeutics announce U S FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Vifor Pharma Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™ injection in hemodialysis patients with moderate-to-severe pruritus Monday, March 8, 2021 1:10PM IST (7:40AM GMT) St. Gallen, Switzerland & Stamford, Conn., United States: FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA™ is 23 August 2021. The FDA stated that

United statesVifor pharmaJulien vignotClaire lacagninaJanhavi mohiteDerek chalmersStefan schulzeNathalie ponnierStern investor relations incSwiss stock exchangeDrug administrationGlobal head corporate communicationsSwiss exchangeInternational journal of nephrologyExchange commissionCara therapeutics inc

Vifor Pharma and Cara Therapeutics announce U S FDA acceptance and Priority Review of NDA for KORSUVA* injection in hemodialysis patients with moderate-to-severe pruritus

Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate-to-severe pruritus If approved, KORSUVA injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210307005039/en/ Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is 23 August 2021. The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the application.

Vifor pharmaJulien vignotClaire lacagninaJanhavi mohiteDerek chalmersStefan schulzeNathalie ponnierStern investor relations incSwiss stock exchangeDrug administrationGlobal head corporate communicationsSwiss exchangeInternational journal of nephrologyExchange commissionCara therapeutics incVifor pharma group

Fresenius Medical Care Asia Pacific Continues to Forge Organization-Wide Inclusion and Diversity

Press release content from Business Wire. The AP news staff was not involved in its creation. Fresenius Medical Care Asia Pacific Continues to Forge Organization-Wide Inclusion and Diversity March 8, 2021 GMT HONG KONG (BUSINESS WIRE) Mar 8, 2021 Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has today launched its Asia Pacific Women’s Leadership Initiative (WLI) as a catalyst to continue driving inclusion and diversity (I&D) amongst its 13,000-strong workforce in the region. Launching on International Women’s Day, the initiative hosted a region-wide virtual event with all staff encouraged to attend. Underpinned by one of the key International Women’s Day missions – to forge inclusive work cultures where women’s careers thrive and achievements are celebrated – the event highlighted the important role of inclusive and diverse leadership in both employee satisfaction and business success. With a key

North sydneyNew south walesNorth pointDonna huaAsia pacificAlexandra villarHarjit gillYork stock exchangeAsia pacific women leadership initiativeFrankfurt stock exchangeExchange commissionFresenius medical care ag coDevelopment departmentCorporate communicationsMckinsey global instituteInternational women day

Cara Therapeutics and Vifor Pharma announce U S FDA acceptance and Priority Review of NDA for

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for . Cara Therapeutics, Inc.March 8, 2021 GMT FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE NEWSWIRE) Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. The FDA stated that currently it is not planning to hold an advisory committee meeting to discuss the

Vifor pharmaJulien vignotClaire lacagninaJanhavi mohiteDerek chalmersStefan schulzeNathalie ponnierStern investor relations incSwiss stock exchangeDrug administrationGlobal head corporate communicationsSwiss exchangeInternational journal of nephrologyExchange commissionVifor pharma groupNational registry study

German shares gain 0 75 pct at start of trading on Monday

German shares gain 0 75 pct at start of trading on Monday
pakistantelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pakistantelegraph.com Daily Mail and Mail on Sunday newspapers.

Goldman sachsStatistical officeFresenius medical careFederal statistical officeகோல்ட்மேன் சாக்ஸ்புள்ளிவிவர அலுவலகம்ப்ரேசெனிுச் மருத்துவ பராமரிப்புகூட்டாட்சியின் புள்ளிவிவர அலுவலகம்